
Takeda A/S under frivillig likvidation

Delta Park 45, DK-2665 Vallensbaek Strand

Annual Report for 1 April 2023 – 31 March 2024

CVR No 28 31 35 19

The Annual Report was
presented and adopted at
the Annual General
Meeting of the Company on 28/08/2024

Ole Nørgaard
Chairman

Contents

	<u>Page</u>
Management's Statement and Auditor's Statement	
Management's Statement	1
Independent Auditor's Report	2
Company information	
Company information	5
Management's review	6
Financial Statement	
Income Statement 1 April – 31 March	7
Balance Sheet 31 March	8
Statement of Changes in Equity	10
Notes to the Financial Statement	11

Management's Statement

The Liquidators have today considered and adopted the Annual Report of Takeda A/S under frivilling likvidation for the financial year 1 April 2023 – 31 March 2024.

The Annual Report is prepared in accordance with the Danish Financial Statement Act.


In our opinion the Financial Statements give true and fair view of the financial position at 31 March 2024 of the Company and of the results of the Company operations for 2023/2024.

In our opinion, Management's Review includes true and fair account of the matters addressed in the Review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Vallensbaek Strand, 28 August 2024

Liquidator



Troels Mørch Tuxen



Ole Nørgaard

Independent Auditor's Report

To the shareholders of Takeda A/S under frivillig likvidation

Opinion

We have audited the financial statements of Takeda A/S under frivillig likvidation for the financial year 1 April – 31 March 2024 comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 March 2024 and of the results of the Company's operations for the financial year 1 April – 31 March 2024 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter in the financial statements

Without modifying our audit opinion, we refer to the fact that the Company has entered into solvent liquidation. Consequently, the annual report is not prepared in accordance with the going concern basis of accounting.

The liquidator's responsibility for the financial statements

The liquidator is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. The liquidator is further responsible for such internal control that he determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the liquidator is responsible for selecting and applying appropriate accounting policies and making such accounting estimates that are necessary for the purpose of the Company's liquidation.

Independent Auditor's Report

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the liquidator
- evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Independent Auditor's Report

Statement on the liquidator's review

The liquidator is responsible for the Liquidator's review.

Our opinion on the financial statements does not cover the Liquidator's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Liquidator's review and, in doing so, consider whether the Liquidator's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Liquidator's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Liquidator's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Liquidator's review.

Copenhagen, 28 August 2024

KPMG

Statsautoriseret Revisionspartnerselskab

CVR no. 25 57 81 98



Sara Carstensen

State Authorised Public Accountant

mne34191

Company Information

The Company	Takeda A/S under frivilling likvidation Delta Park 45 DK-2665 Vallensbæk Strand CVR No. 28 31 35 19 Municipality of reg. office: Høje-Taastrup
Liquidator	Troels Mørch Tuxen Ole Nørgaard
Auditors	KPMG Statsautoriseret Revisionspartnerselskab Dampfærgevej 28 DK-2100 København Ø
Lawyers	Plesner
Bankers	Nordea Bank Danmark A/S

Management's Review

Key activities

Takeda A/S under frivilling likvidation is a company in the Takeda Group in which the Japanese pharmaceutical company, Takeda Pharmaceutical Company Limited, is the ultimate parent company.

The Company is under liquidation currently awaiting the outcome of an ongoing Danish tax litigation case. The process of liquidating the entity will be continued after the tax case has been closed. Liquidation is not expected to be completed prior to 2024.

The Company's capital and the activities in the Company are administrated by the Takeda Group in cooperation with the Liquidators of the Company.

The solvent liquidation of the Company

At the extraordinary general meeting on 19 February 2019, it was decided to dissolve the Company under the rules of solvent liquidation of the Danish Companies Act.

The Company's former Executive Board of Directors have resigned as a result of the resolution to dissolve the Company and have been replaced by the Liquidators.

Development in the year

The income statement of the Company for 2023/2024 shows a profit of DKK 3,058k, and at 31 March 2024 the balance sheet of the Company shows equity of DKK 25,028.

The past year

The result for 2023/2024 is in line with expectations due to the interest received by the tax authorities.

Unusual events

The financial position at 31 March 2024 of the Company and the results of the activities of the Company for the financial year for 2023/24 have not been affected by any unusual events.

Recognition and measurement in the Annual Report have not been subject to any uncertainty.

Income Statement 1 April – 31 March

	<u>Note</u>	<u>2023/2024</u> DKK thousands	<u>2022/2023</u> DKK thousands
Revenue		0	0
Other external expenses	1	-3,486	193
Gross profit		-3,486	193
Loss/profit before financial income and expenses		-3,486	193
Financial income	2	4,599	24,849
Financial expenses		-32	-94
Profit before tax		1,082	24,948
Tax on profit for the year		1,976	37,875
Net profit for the year		3,058	62,823

Balance Sheet 31 March

Assets

	<u>Note</u>	<u>2023/2024</u> DKK thousands	<u>2022/2023</u> DKK thousands
Deposits	3	17,989	17,943
Fixed asset investments		17,989	17,943
Fixed assets		17,989	17,943
Receivables from group enterprises		7,154	47,036
Other receivables		0	0
Deferred tax asset		872	787
Corporation tax		0	59,858
Receivables		8,026	107,681
Current assets		8,026	107,681
Assets		26,015	125,624

Balance Sheet 31 March

Liabilities and equity

	<u>Note</u>	<u>2023/2024</u> DKK thousands	<u>2022/2023</u> DKK thousands
Share capital		995	995
Liquidation account		24,034	20,976
Proposed dividend for the year		0	100,000
Equity	4	25,028	121,970
Payables to group enterprises		986	78
Other payables		0	3,575
Short-term liabilities		986	3,653
Liabilities		986	3,653
Liabilities and equity		26,015	125,624
Distribution of profit	5		
Related parties	6		
Accounting Policies	7		
Contingent assets, liabilities and other financial obligations	8		

Statement of Changes in Equity

	<u>Share capital</u> DKK thousands	<u>Retained earnings</u> DKK thousands	<u>Liquidation account</u> DKK thousands	<u>Proposed dividend</u> DKK thousands	<u>Total</u> DKK thousands
Equity at 1 April	995	0	20,976	100,000	121,971
Transfer to the liquidation account	0	-3,058	-3,058	0	0
Distribution of profit of the year	0	3,058	0	0	3,058
Dividend	0	0	0	-100,000	-100,000
Equity at 31 March	995	0	24,034	0	25,029

Notes to the Financial Statement

1 Other external expenses

External expenses relate to tax consulting and judgment in the Danish WHT.

2 Financial income

	<u>2023/2024</u> DKK thousands	<u>2022/2023</u> DKK thousands
Interest received from group enterprises	1,644	362
Other financial income	2,909	24,437
Exchange gains	46	50
	4,599	24,849

3 Deposits

Deposit of Bech-Bruun Law Firm P/S and the liquidators in connection with the liquidation process.

4 Equity

The share capital consists of 13,362,814 shares of a nominal value of EUR 0.01 each, equivalent to DKK 995k. The share capital is not divided into shares and no shares carry any specific rights.

5 Distribution of profit

	<u>2023/2024</u> DKK thousands	<u>2022/2023</u> DKK thousands
Retained earnings	3,058	0
Proposed dividend for the year	0	62,823
	3,058	62,823

Notes to the Financial Statement

6 Related parties

Ownership

The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital:

Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-chome Chuo-ku, Osaka-shi 540-8645, Japan

Consolidated Financial Statements

The company is included in the consolidated financial statements of the parent company

Takeda Pharmaceutical Company Limited, Japan

The consolidated financial statement of the parent company can be obtained at the address:

Takeda Pharmaceutical Company Limited

1-1, Doshomachi 4-chome Chuo-ku

Osaka-shi 540-8645

Japan

7 Accounting Policies

The Annual Report of Takeda A/S under frivilling likvidation for 2023/2024 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B.

Due to liquidation, assets and liability are recognized at expected realizable values, and provisions has been made for liquidation costs in debt in Financial Statement.

The Financial Statements for 2023/2024 are presented in DKK thousands.

Notes to the Financial Statement

7 Accounting Policies (continued)

Recognition and measurement

Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.

Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

Certain financial assets and liabilities are measured at amortized cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortized cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortization of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.

Recognition and measurement take into account predictable losses and risks occurring before the presentation of the Annual Report which confirm or invalidate affairs and conditions existing at the balance sheet date.

Danish kroner is used as the measurement currency. All other currencies are regarded as foreign currencies

Translation policies

Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Exchange differences arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement.

Receivables, payables and other monetary items in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date. Any differences between the exchange rates at the balance sheet date and the rates at the time when the receivable or the debt arose are recognized in financial income and expenses in the income statement.

Notes to the Financial Statement

7 Accounting Policies (continued)

Income statement

Other external expenses

Other external expenses comprise primarily tax consulting.

Financial income and expenses

Financial income and expenses include interest, amortization of finance costs, realized and unrealized foreign exchange gains and losses as well as other financial income and expenses related to the financial year. Unrealized foreign exchange gains and losses include changes in the fair value of derivative financial statements concluded to hedge fair value.

Tax on loss for the year

The Company is jointly taxed with wholly owned Danish subsidiaries. The tax effect of the joint taxation is allocated to Danish enterprises in proportion to their taxable income.

Balance Sheet

Receivables

Receivables are recognized in the balance sheet at amortized cost, which substantially corresponds to nominal value. Provisions for estimated bad debts are made.

Dividend

Dividend distribution proposed by Management for the year is disclosed as a separate equity item.

Deferred tax assets and liabilities

Deferred income tax is measured using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes on the basis of the intended use of the asset and settlement of the liability, respectively.

Deferred tax assets, including the tax base of tax loss carry-forwards, are measured at the value at which the asset is expected to be realized, either by elimination in tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity.

Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation at the balance sheet date when the deferred tax is expected to crystallize as current tax. Any changes in deferred tax due to changes to tax rates are recognized in the income statement.

Notes to the Financial Statement

7 Accounting Policies (continued)

Current tax receivables and liabilities

Current tax liabilities and receivables are recognized in the balance sheet as the expected taxable income for the period adjusted for tax on taxable incomes for prior years and tax paid on account. Extra payments and repayment under the on-account taxation scheme are recognized in the income statement in financial income and expenses.

Financial liabilities

Other liabilities are measured at amortized cost, substantially corresponding to nominal value.

8 Contingent assets, liabilities and other financial obligations

Contingent assets and liabilities

There is no contingent assets or liabilities to disclose.